메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

ALR TECHNOLOGIES TO RELAUNCH THE GLUCURVE PET CGM IN JANUARY…

SINGAPORE, Dec. 8, 2025 -- ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces the successful completion of internal manufacturing testing on the GluCurve Pet CGM ("GluCurve") showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. GluCurve is the first and only diabetic monitoring system built specifically for veterinary use on cats and dogs. A pet-friendly Continuous Glucose Monitor
- 김갑성 기자
- 2025-12-08 22:14
Zymedi Announces "rapaprutug" as the International Nonp…

INCHEON, South Korea, Dec. 8, 2025 -- Zymedi (CEO Sunghoon Kim) announced that the World Health Organization (WHO) has assigned rapaprutug as the International Nonproprietary Name (INN) for the company's first-in-class antibody therapy ZMA001, being developed as a treatment for pulmonary arterial hypertension (PAH). The assignment of the name rapaprutug (development code: ZMA001) marks a key global milestone and establishes a unified scientific identity for Zymedi's lead candidate as it advances through development. The antibody is currently being evaluated in an ongoing Phase 1 clinic
- 김갑성 기자
- 2025-12-08 22:00
Lunit Submits 510(k) Application for Image-Based Breast Canc…

Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for Lunit INSIGHT Risk, a mammography-based five-year breast cancer risk prediction model. Potential clearance is expected in 2026. Lunit INSIGHT Risk estimates a woman's five-year bre
- 김갑성 기자
- 2025-12-08 22:00
PT Fapon and PT Bio Farma Forge Strategic Partnership to Adv…

DONGGUAN, China, Dec. 8, 2025 -- PT Fapon Bioindustries Indonesia (referred to as "PT Fapon") and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as "Bio Farma") officially signed a cooperation agreement at Fapon's headquarters in Dongguan. The partnership is centered on the local manufacturing, and commercialization of IVD products in Indonesia. Mrs. Dyah, Chief Executive Officer of Fapon Indonesia Market, and Mr. Dicky, Head of the Business Development Division at Bio Farma, formally executed the agreement on behalf of their respe
- 김갑성 기자
- 2025-12-08 20:47
Servier's Voranigo® (vorasidenib) Receives Prix Galien Award…

Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. These awards across several geographies recognize the progress represented by Voranigo® for patients living with glioma. SURESNES, France, Dec. 8, 2025 -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that Voranigo® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases, during a ceremony held in
- 김갑성 기자
- 2025-12-08 20:24
Aurora Names Seasoned Global CPG Executive to Lead Austr…

NASDAQ | TSX: ACB EDMONTON, AB, Dec. 8, 2025 -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving growth in these key markets, drawing on decades of global experience in fast moving, regulated industries. "I'm excited to join Aurora at an inflection point in the company's global leadership and to work alongside a team dedicate
- 김갑성 기자
- 2025-12-08 20:00
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Place…

- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. - ASC30 titrated weekly to target dose demonstrated approximately one-half the rate of vomiting observed with orforglipron titrated weekly. - No hepatic safety signal was observed, and no elevations of alanine transaminase (ALT), aspartate aminotransferase (AST) or total bilirubin (TBL) were observed. - Two conference calls/webcasts are scheduled to discuss the results, including a
- 김갑성 기자
- 2025-12-08 17:40
ELFBAR takes a bold step in restrained design with its award…

LONDON, Dec. 8, 2025 -- Leading global vape brand ELFBAR today announced it has earned three global design awards — the Pentawards, the Red Dot Award*, and the London Design Awards — for its boldly restrained design of the ELFA PRO Nicotine Reduction Kit, the first ever of its kind created to help adult smokers and vapers quit nicotine for good. Visualising the journey beyond nicotine The ELFA PRO Nicotine Reduction Kit, a classic ELFBAR pod system, is designed as a three-phase, 90-day pathway that gradually lowers nicotine intake from 2% to 1% and then to 0%. Th
- 김갑성 기자
- 2025-12-08 17:00
엘프바의 과감한 시도, 절제된 디자인이 돋보이는 니코틴 감축 키트의 잇따른 수상

런던 2025년 12월 8일 -- 세계적인 전자담배 브랜드 엘프바(ELFBAR)는 오늘 성인 흡연자와 전자담배 애용자의 금연을 돕는 업계 최초의 엘파 프로 니코틴 감축 키트(ELFA PRO Nicotine Reduction Kit)가 대담하면서도 절제된 디자인에 힘입어 세계적인 디자인 어워드인 펜타어워즈(Pentawards), 레드닷 어워드(Red Dot Award)*, 런던 디자인 어워즈(London Design Awards)를 잇따라 수상하는 쾌거를 이뤘다고 발표했다. 체계적인 금연 계획 엘프바의 전통적인 액상 팟 교체 방식의 엘파 프로 니코틴 감축 키트는 90일 동안 3단계로 나눠 니코틴 함유량을 2%에서 1%, 그리고 최종적으로 0%로 점차 줄이도록 설계되었다. 금연 과정은 1개월 단위의 3단계(1~30일 차, 31~60일 차, 61~90일 차)로 나뉘어 있으며, 단계마다 니코틴 함량이 대폭 줄어든다. 제품 사용자가 니코틴에서 완전히 해방될 수 있도록 돕는 각 단계는 행동 변화에 흔히 수반되는 감정적 흐름을 반영하여 '각성(Awaken)', '수용(Embrace)', '변화(Trans
- 김갑성 기자
- 2025-12-08 17:00
Qualcomm Highlights Edge AI Innovation at Qualcomm AI Progr…

[ 메디채널 김갑성 기자 ] Showcasing transformative edge AI innovations across robotics, healthcare and smart city solutions SEOUL, South Korea, Dec. 8, 2025 -- Qualcomm Technologies, Inc. hosted the Qualcomm AI Program for Innovators (QAIPI) 2025 – APAC Demo Day in Seoul, where 15 shortlisted startups from Japan, Singapore, and South Korea presented on-device AI solutions by leveraging Snapdragon® X Series processors, Snapdragon® 8 Series Mobile Platforms and Qualcomm Dragonwing™ products. These solutions demonstrate how real-time, power-efficient AI inference runs directly on Qualcom
- 김갑성 기자
- 2025-12-08 16:28

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 19시 00분